Cellectis SA (CLLS)
4.12
+0.14
(+3.52%)
USD |
NASDAQ |
Feb 25, 15:14
Cellectis Research and Development Expense (Quarterly) : 19.34M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| EDAP TMS SA | 2.438M |
| DBV Technologies SA | 26.82M |
| Ascendis Pharma A/S | 88.09M |
| Akari Therapeutics Plc | 0.2475M |
| Biodexa Pharmaceuticals Plc | -- |